VJHemOnc is committed to improving our service to you

ASH 2019 | Analysis of outcomes of younger CLL patients

VJHemOnc is committed to improving our service to you

Barbara Eichhorst

Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, outlines the results from a pooled analysis of the outcomes of younger (≤ 55 years) compared with older chronic lymphocytic leukemia (CLL) patients receiving first-line treatment in seven phase II or III clinical trials conducted by the German CLL Study Group (GCLLSG). Dr Eichhorst emphasizes that a lot of progress is needed to increase overall survival in younger CLL patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter